Skip to content

Viking Therapeutics

US · VKTX #2352 by market cap Listed 2015
24.77 -1.07 -4.14%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:56

Recent news

  • Rating change
    CCORF Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Cuts Target Price to $106
    Market Newswire · 2026/10/20
  • Company notice
    Viking Therapeutics | 10-Q: Q3 2026 Earnings Report
    SEC · 2026/10/30
  • Company notice
    Viking Therapeutics | 8-K: Current report
    SEC · 2026/9/29
  • Rating change
    Canaccord Genuity Maintains Buy on Viking Therapeutics, Lowers Price Target to $106
    Benzinga · 2026/10/20
  • Maxim Group Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $70
    Market Newswire · 2026/10/31
  • Rating change
    Viking Therapeutics Is Maintained at Buy by Canaccord Genuity
    Dow Jones · 2026/10/20
  • A Quick Look at Today's Ratings for Viking Therapeutics(VKTX.US), With a Forecast Between $85 to $125
    Market Newswire · 2026/10/30
  • Rating change
    UBS Initiates Viking Therapeutics at Buy With $94 Price Target
    MT Newswires · 2026/10/15
  • Company notice
    Viking Therapeutics | 424B5: Prospectus
    SEC · 2026/9/25
  • Viking Therapeutics Gains Amid Report of Renewed Takeover Interest
    Seeking Alpha · 2026/11/14
  • Rating change
    H.C. Wainwright Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $102
    Market Newswire · 2026/10/14
  • Company notice
    Viking Therapeutics | 8-K: Viking Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
    SEC · 2026/10/29
  • Rating change
    UBS Initiates Coverage On Viking Therapeutics With Buy Rating, Announces Price Target of $94
    Benzinga · 2026/10/16
  • CCORF Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Raises Target Price to $118
    Market Newswire · 2026/10/31
  • Viking Therapeutics Announces Two Poster Presentations at ObesityWeek® 2026
    PR Newswire · 2026/11/9
  • Company notice
    Viking Therapeutics | SCHEDULE 13G/A: Others
    SEC · 2026/11/6
  • Rating change
    Canaccord Genuity Maintains Buy on Viking Therapeutics, Raises Price Target to $118
    Benzinga · 2026/10/31
  • Rating change
    A Quick Look at Today's Ratings for Viking Therapeutics(VKTX.US), With a Forecast Between $34 to $125
    Market Newswire · 2026/10/29
  • Rating change
    Viking Therapeutics Price Target Announced at $94.00/Share by UBS
    Dow Jones · 2026/10/16
  • Rating change
    CCORF Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $114
    Market Newswire · 2026/10/15
  • Company notice
    Viking Therapeutics | 424B5: Prospectus
    SEC · 2026/9/25
  • CORRECTION: Viking Therapeutics Ticker Is "VKTX" Not "VIK"
    Benzinga · 2026/10/29
  • Rating change
    A Quick Look at Today's Ratings for Viking Therapeutics(VKTX.US), With a Forecast Between $87 to $125
    Market Newswire · 2026/9/23
  • Rating change
    Jefferies Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $101
    Market Newswire · 2026/7/30
  • H.C. Wainwright Keeps Their Buy Rating on Viking Therapeutics (VKTX)
    TipRanks · 2026/10/14

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-11-20 19:56:05 · For reference only, not investment advice and not tailored to your situation.

Viking Therapeutics discussion 0 comments

Add a comment